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Abstract
Background: Hand-foot-and-mouth disease (HFMD) is caused mainly by the human enterovirus type 71 (HEV71)
and the Coxsackievirus A group type 16 (CVA16). Large outbreaks of disease have occurred frequently in the Asia-
Pacific region. Reliable methods are needed for diagnosis of HFMD in childen. IgM-capture ELISA, with its notable
advantages of convenience and low cost, provides a potentially frontline assay. We aimed to evaluate the newly
developed IgM-capture ELISAs for HEV71 and CVA16 in the diagnosis of HFMD, and to measure the kinetics of IgM
over the course of HEV71 or CVA16 infections.
Results: We mapped, for the first time, the kinetics of IgM in HEV71 and CVA16 infection. HEV71- and CVA16-IgM
were both detectable in some patients on day 1 of illness, and in 100% of patients by day 5 (HEV71) and day 8
(CVA16) respectively; both IgMs persisted for several weeks. The IgM detection rates were 90.2% (138 of 153 sera)
and 68.0% (66 of 97 sera) for HEV71 and CVA16 infections, respectively, during the first 7 days of diseases. During
the first 90 days after onset these values were 93.6% (233 of 249 sera) and 72.8% (91 of 125 sera) for HEV71 and
CVA16 infections, respectively. Some cross-reactivity was observed between HEV71- and CVA16-IgM ELISAs. HEV71-
IgM was positive in 38 of 122 (31.1%) CVA16 infections, 14 of 49 (28.6%) other enteroviral infections and 2 of 105
(1.9%) for other respiratory virus infected sera. Similarly, CVA16-IgM was apparently positive in 58 of 211 (27.5%)
HEV71 infections, 16 of 48 (33.3%) other enterovirus infections and 3 of 105 (2.9%) other respiratory virus infected
sera. Nevertheless, the ELISA yielded the higher OD450 value of main antibody than that of cross-reaction antibody,
successfully identifying the enteroviral infection in 96.6% (HEV71) and 91.7% (CVA16) cases. When blood and rectal
swabs were collected on the same day, the data showed that the agreement between IgM-capture ELISA and real-
time RT-PCR in HEV71 was high (Kappa value = 0.729) while CVA16 somewhat lower (Kappa value = 0.300).
Conclusions: HEV71- and CVA16-IgM ELISAs can be deployed successfully as a convenient and cost-effective
diagnostic tool for HFMD in clinical laboratories.
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Hand-foot-and-mouth disease (HFMD), characterized by
fever and acute vesicular eruptions of palms, soles of the
feet and mouth (herpangina), is a common exanthema
in young children. It is caused by members of the non-
polio Enterovirus genus (family Picornoviridae),s u c ha s
Coxsackievirus A (CVA) and B, Echovirus 4, 6 and 7,
particularly CVA16 and human enterovirus (HEV) 71.
Outbreaks have occurred recently in the Asia-Pacific
region: Malaysia (2000-2003) [1], Taiwan (1998-2005)
[2,3], Singapore (2000) [4], Brunei (2006) [5], Thailand
(2008-2009) [6], Korea (2008-2009) [7], and Hong Kong
(2008) [8]. In mainland China, large epidemics of
HFMD have been reported: Shenzhen (1999-2004) [9],
Beijing (2008) [10], and Fuyang city (2008) [11]. Surveil-
lance studies have indicated that HEV71 and CVA16
circulate widely in central and southern China. The
severe complications and even fatal cases in young chil-
dren associated with HEV71 make HFMD an important
health concern. With large outbreaks occurring fre-
quently and the increased concern of fatal HFMD
caused by HEV71, a rapid, specific, and cost-effective
assay to identify the HFMD-causing enterovirus is of
great importance. Recognition of the causative agent for
HFMD mainly relies on laboratory identification of the
virus so that treatment and effective public health mea-
sures can be taken early.
Diagnostic techniques include time consuming and
labor intensive methods such as virus isolation, a neu-
tralization test, and RT-PCR for viral RNA detection. In
contrast, newly developed IgM-capture ELISAs for
HEV71 [12,13] and CVA16 [14] are rapid and conveni-
ent for large numbers of specimens. Previously, capture
ELISAs for HEV71- and CVA16-IgM were established,
which show good efficiency for screening HFMD
patients [12,14]. An understanding of the kinetic profiles
of the IgM antibodies and the diagnostic characteristic
of these assays is needed to substantiate their validity. In
this study, we aimed to evaluate IgM-capture ELISAs
for HEV71 and CVA16 for diagnosis of HFMD in pedia-
tric patients, and to follow the kinetics of IgM antibo-
dies over the course of these infections.
Materials and methods
Patients and clinical samples
HFMD patients with clinic features of herpangina, asep-
tic meningitis, and encephalitis, hospitalized in Zhujiang
Hospital from March 2009 to December 2010, were stu-
died. Laboratory diagnosis of all these patients showed
them to be infected with HEV71, CVA16 or other enter-
oviruses as detected on rectal swabs using real-time RT-
PCR plus virus isolation in some cases. Selected cases
were confirmed by the neutralization test. The assay
results showed 134 HFMD patients (86 male and 48
female, aged 4 months to 14.1 years, median 2.17 years)
with HEV71 infection, 67 HFMD patients (49 male and
18 female, aged 6 months to 7.0 years, median 2.17
years) with CVA16 infection, and 29 HFMD patients (21
male and 8 female, aged 5 months to 5.6 years, median
1.83 years) with other enteroviral infections. A total of
434 acute- and convalescent-phase serum specimens
were collected between days 1 and 158 after the onset
of symptoms from these 230 HFMD patients (a single
sample from 69 patients, two from 139 individuals,
three from 18 patients, two from four individuals and
six from one patient). Nineteen consecutive sera from
one patient, confirmed as infected with HEV71 by real-
time RT-PCR in combination with virus isolation, were
assayed for HEV71-IgM during the course of the
disease.
As controls, 105 sera from 75 patients with acute
respiratory infections were collected. All these patients
had been laboratory-confirmed previously as being
infected with respiratory syncytial virus (RSV, 40
patients), adenovirus (9), influenza A virus (5), influenza
B virus (2), parainfluenza virus (5), human rhinovirus
(3), human metapneumovirus (3) and other respiratory
viruses (8) by real-time RT-PCR and/or virus isolation.
Real-time RT-PCR and VP1 semi-nested RT PCR
Viral RNA extraction was performed on swab specimens
using the QIAamp Viral RNA Mini Kit (Qiagen). Real-
time RT-PCR was performed in a Lightcycler 1.2 (Roche)
using Pan-Enterovirus-, HEV71- and CVA16-specific
detecting kits (Da An Gene Co., Ltd.). After 25 min of
reverse transcription at 40°C and denaturation at 94°C for
3 min, 40 cycles of amplification (denaturation: 93°C, 15
sec; annealing/elongation: 55°C, 45 sec) were used. The
semi-nested RT-PCR was as described previously [15]
using RNA extracted from rectal swabs. Sequencing of the
amplified VP1 gene product identified the serotype.
Virus Isolation
Viral isolation was attempted on selected rectal swabs
that were real-time RT-PCR positive. After shaking vig-
orously and centrifugation (4°C, 10,000 × g, 20 min),
samples were sterilized by filtration (0.22 μm Millipore
express
® membrane) and used to inoculate human rhab-
domyosarcoma (RD) and/or laryngeal carcinoma cells.
Once a complete cytopathic effect (CPE) was noted, cul-
tures were harvested and viral identification was per-
formed by real-time RT-PCR as described above.
Neutralization test
HEV71 and CVA16 specific neutralizing antibodies were
detected according to a standard protocol [16]. Briefly,
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and incubated at 34°C for 2 h. The mixtures were added
to replicate microplate cultures of RD cells and incu-
bated at 34°C for 7 days. CPE was observed under a
microscope after 2 to 7 days. The highest dilution that
prevented the occurrence of the CPE was designated as
the neutralizing antibody titer.
IgM-capture ELISA
The IgM-capture ELISA for HEV71 and CVA16 has
been described previously [12,14]. The cutoff value was
set as 0.1 plus mean OD450 value of negative controls.
An S/CO (sample/cutoff) value greater than 1.0 indi-
cated a positive result.
Statistical analysis
Sensitivity and specificity were calculated from the
ELISA and real-time RT-PCR results. Differences
between the proportions of positive results were com-
pared by McNemar’s chi-square test using SPSS soft-
ware (version.13.0) and considered to be significant
when P < 0.05.
Results
Kinetics of IgM antibodies in HEV71 and CVA16 infections
To measure the kinetics of IgM antibodies, serum sam-
ples were obtained on day 1 to 158 after onset from 134
HEV71 infected patients (256 serum samples) and 67
CVA16 infected patients (129 serum samples) and were
tested using HEV71- and CVA16-IgM ELISAs. HEV71-
and CVA16-IgM were both detectable on day 1 of ill-
ness and persisted for several weeks (Figure 1). The
100% positive rate was reached at day 5 (HEV71) and
day 8 (CVA16) respectively. By twenty weeks after
onset, the IgM detection rate had decreased substan-
tially. None of seven HEV71 sera taken after 90 days of
disease were HEV71-IgM positive and only one of four
CVA16 sera taken after 90 days of disease was weakly
positive for CVA16-IgM (S/CO value = 1.09).
The overall sensitivity was 90.2% (138 of 153 sera) for
HEV71 and 68.0% (66 of 97 sera) for CVA16 infections
during the first 7 days and 93.6% (233 of 249 sera) for
HEV71 and 72.8% (91 of 125 sera) for CVA16 infections
d u r i n gt h ef i r s t9 0d a y so fd i s e a s e( T a b l e1 ) .T h ep o s i -
tive rate of HEV71-IgM was significantly higher than
that of CVA16-IgM during the first week (P =0 . 0 0 0 ) ,
and also over the first 90 days of disease (P = 0.000).
One HEV71 infected patient, who provided 19 consecu-
tive sera, tested positive for HEV71-IgM from day 5 to
74. Antibody remained high (S/CO>7.0) until day 43,
then declined (S/CO: 1.5-4.3).
Cross-reactivity of HEV71- and CVA16-IgM ELISAs
To measure the specificity of the two IgM-capture ELI-
SAs, HEV71-IgM was measured in 122 sera from 67
CVA16 patients and 49 sera from 29 other enterovirus
infected patients. Similarly, CVA16-IgM was measured
in 211 sera from 116 HEV71 patients and 48 sera from
29 other enterovirus infected patients. We also mea-
sured both IgMs in 105 sera from 75 respiratory virus
infected patients to further test the specificity. Serotyp-
ing by semi-nested RT-PCR [15] of the 29 other entero-
virus infected patients showed CVA6 in four individuals,
CVA10 in two, one each of CVA21, CVB2, Echo 16 or
Echo 25, and 19 untyped; the latter were further
Figure 1 The positive rate of detecting the HEV71- (●) and CVA16-specific (○) IgM as a function of time after the onset of symptoms.
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neutralization test. HEV71-IgM was positive in 38 of
122 CVA16, 14 of 49 other enterovirus and two (both
from one patient co-infected with RSV subgroup A and
B) of 105 respiratory virus infected sera. The specificity
was 69.6% (52/171) compared to other enteroviruses
and 98.1% (2/105) compared to other respiratory viruses
(Table 1). CVA16-IgM was apparently positive in 58 of
211 HEV71, 16 of 48 other enterovirus and 3 (from two
patients co-infected with RSV subgroup A and B and
one with RSV subgroup B) of 105 respiratory virus
infected sera, giving a specificity of 71.4% (74/259) com-
pared to other enteroviruses and 97.1% (3/105) com-
pared to other respiratory viruses. The positive and
negative predictive values were 81.3% (95% confidence
interval: 76.9-85.1%) and 91.0% (95% confidence interval:
87.5-93.8%) for HEV71, 54.4% (95% confidence interval:
48.3-60.9%) and 88.6% (95% confidence interval: 85.1-
91.4%) for CVA16, respectively (Table 1).
To further analyze the cross-reactivity of the assays, a
total of 206 sera from 134 HEV71 patients and 119 sera
from 66 CVA16 infected patients were tested for both
HEV71- and CVA16-IgM simultaneously (Figure 2). For
the HEV71-infected patients (Figure 2A), 199 of 206
samples were positive for HEV71-IgM (95.7%) while the
cross-reactivity towards CVA16-IgM was 28.2% (58/206).
However, of the 58 CVA16-IgM positive sera, the ratio of
OD450 value for HEV71-IgM divided by that for CVA16-
IgM greater than 1.0 can successfully identify 56 (96.6%)
HEV71 infections (Figure 2A, inset). For the CVA16
patients (Figure 2B), CVA16-IgM was detected in only 83
of 119 samples (69.7%) while cross-reactivity towards
HEV71-IgM was seen in 30.3% (36/119). While of the 36
HEV71-IgM positive sera, the ratio of OD450 value for
CVA16-IgM divided by that for HEV71-IgM greater than
1.0 can successfully identify 33 (91.7%) CVA16 infections
(Figure 2B, inset).
Correlation between real-time RT-PCR and IgM-capture
ELISA results
In all patients, HEV71 or CVA16 was identified by real-
time RT-PCR of a rectal swab, but this was not always
taken on the same day that serum was collected. Subsets
of the data, where both samples (111 HEV71 and 53
CVA16) were collected within 24 hours of one another
were analyzed. For HEV71, the difference between
ELISA and real-time RT-PCR was not statistically signif-
icant (McNemar’s chi-square test exact P = 0.648) and
the measure agreement was high (Kappa value = 0.729).
For CVA16, the difference between ELISA and real-time
RT-PCR was not statistically significant (McNemar’s
chi-square test exact P = 0.885) but the measure agree-
ment was relatively low (Kappa value = 0.300). In other
respects, the data are similar to those in Figure 1 in that
IgM increased during the very early acute phase and
reached the 100% positive rate by day 4 (HEV71) or 8
(CVA16). The sensitivity for HEV71-IgM was 90.1%
(95% confidence interval: 84.1-94.4%) while that for
CVA16-IgM was 56.6% (95% confidence interval: 44.5-
67.9%).
Discussion
Conventional methods for diagnosis of HEV71 and
CVA16 infection (virus isolation, neutralization or RT-
PCR) are slow, complex and/or costly, do not lend
themselves to large number of specimens and are, there-
fore, unsuited to the clinics of developing countries.
IgM-capture ELISA, with its notable advantages of con-
venience and low cost, provides a potentially frontline
assay for diagnosis of HFMD.
We mapped, for the first time, the kinetics of IgM in
HEV71 and CVA16 infection. In 138/153 sera of HEV71
and 66/97 sera of CVA16, IgM was detected during the
acute phase (within 7 days after symptom onset), consis-
tent with Wang’ s study [13] for HEV71. The positive
rate reached 100% at day five and eight, somewhat later
than that of nucleic acid detection of HEV71 in throat
and fecal samples from HFMD patients. However, the
IgM is maintained for several months while the detec-
tion rate of nucleic acid fell markedly during 9-12 days
after onset of disease [17]. For example, IgM was
detected by Wang on day 94, while we found two cases,
one each of HEV71 and CVA16 infection, where the
corresponding IgM was detectable on day 74 and 87
respectively. However, 3-4 months after onset, both
IgMs had largely declined to undetectable levels. Never-
theless, it should be noted that these results were
obtained from multiple individuals and need to be
Table 1 The positive detection rate of HEV71- and CVA16-IgM antibodies by the IgM-capture ELISA.
No. of positive/No. of sera Positive predictive value
(95% confidence interval)
Negative predictive value
(95% confidence interval)
IgM-
capture
ELISAs
HEV71
infected
sera
CVA16
infected
sera
Other enterovirus
infected sera
Respiratory virus
infectious sera
HEV71-IgM 233/249 38/122 14/49 2/105 81.3% (76.9-85.1%) 91.0% (87.5-93.8%)
CVA16 -IgM 58/211 91/125 16/48 3/105 54.4% (48.3-60.9%) 88.6% (85.1-91.4%)
Note: The data were collected during the first 90 days of disease.
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Page 4 of 7Figure 2 OD450 values and ratio for HEV71-IgM and CVA16-IgM in HEV71 or CVA16 infected sera collected at various days after onset
of symptoms. Panel A shows the OD450 values for HEV71 infected patients; values greater than cutoff (horizontal line) represent a positive
result. The inset shows the ratio of OD450 values for HEV71-IgM divided by that for CVA16-IgM. Panel B shows the OD450 values for CVA16
infected patients; values greater than 1.0 (horizontal line) represent a positive result. The inset shows the ratio of OD450 values for CVA16-IgM
divided by that for HEV71-IgM.
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patients.
Recent results may be compared with those reported
previously. The sensitivity for HEV71 (93.6%) is consis-
tent with that reported (94.1%) [12], while that for
CVA16 IgM (72.8%) was somewhat lower than that
found earlier (84.6%) [14]. The discrepancy may due to
the time when the sera were collected; our results show
that CVA16 IgM is detectable in only 68% of patients in
days 1-7 of illness, but rises to 100% on days 8-11.
When blood and rectal swabs were collected on the
same day, the agreement between capture-ELISA and
real-time RT-PCR in both HEV71 and CVA16 infections
suggested both capture-ELISAs perform as well as RT-
PCR in diagnosing HFMD and could be deployed suc-
cessfully in clinical and public health laboratories.
Because the sample size was relatively small, particularly
for CVA16, it is difficult to compare the sensitivity
results with our larger data set.
We observed significant cross-reactivity between
HEV71- and CVA16-IgM ELISAs and several reasons
can be advanced for this apparent lack of specificity.
First, co-infection by the two viruses could occur, lead-
ing to simultaneous production of both HEV71- and
CVA16-IgMs. This is ruled out by the real-time RT-
PCR results, which never detected both of these two
viruses. Second, there may have been prior infection
with the other virus. If this prior infection had been sev-
eral months before clinical presentation, the dominant
immunoglobulin isotype would be IgG, with the level of
IgM low or undetectable. More recent prior infection
could be the explanation; although the virus itself would
have been cleared and not detected, the corresponding
IgM can persist for several weeks. In this case, it would
be expected that the cross-reactive IgM would have
been detected in the earliest samples that were collected.
Figure 2 shows that cross-reactivity is delayed, taking a
few days to become evident.
The third hypothesis, which we favor, is that the IgMs
may recognize a common epitope between these two
related viruses. Homology between HEV71 and CVA16
is 77% at the genome level and 89% for amino acid
sequences [18]. The resulting antigenic similarity means
that infection with one virus could elicit antibodies
against a second enterovirus serotype. This hypothesis is
supported by the observed cross-reactivity with other
enteroviruses (Table 1).
For example, 38 of 122 (31.1%) CVA16 infected sam-
ples were positive for HEV71-IgM, a value comparable
t ot h e1 4o f4 9( 2 8 . 6 % )s a m p l e sf r o mo t h e re n t e r o v i r a l
infections. In contrast, only 2o f1 0 5( 1 . 9 % )r e s p i r a t o r y
virus infected sera were HEV71-IgM positive. This is
strong evidence against the hypothesis that this cross-
reactivity is due to a recent prior infection to HEV71. It
seems unlikely that about 30% of the patients infected
with CVA16 or with other enteroviruses were previously
infected by HEV71, while only 2% of the respiratory
virus infected patients had this prior infection. Similarly,
CVA16-IgM was apparently positive in 58 of 211
(27.5%) HEV71 infected samples, 16 of 48 (33.3%) of
other enterovirus infections, but only 3 of 105 (2.9%) for
other respiratory virus infected sera. It was demon-
strated, by virus neutralization tests, that none of the
patients infected with other enteroviruses or other
respiratory viruses, was virus-positive for HEV71 or
CVA16.
We suggest that infection with either HEV71 or
CVA16 results in several IgMs, some that are specific
for the infecting virus and others that cross-react with
related enteroviruses. From a practical standpoint,
ELISA yielding the higher OD450 value was successful in
identifying whether the enteroviral infection was by
HEV71 or CVA16 in most cases. This is an important
result because it can be used as a predictor to distin-
guish these two causes HFMD. A small proportion of
HEV71-infected children develop severe and sometimes
fatal neurological and systemic complications over days
or even hours [19] so early diagnosis of the infecting
virus is crucial.
Conclusions
This study represents the first report of the kinetics of
IgM in HEV71 and CVA16 infections. The IgM-capture
ELISAs for HEV71 and CVA16 were found to be highly
effective in correctly identifying the infecting virus. ELI-
SAs have the advantage over RT-PCR to provide a con-
venient and relatively rapid diagnostic tool for HFMD
infections. Assaying for both HEV71-IgM and CVA1-
IgM can be deployed successfully as a cost-effective
diagnosis of HFMD in clinical and public health
laboratories.
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